October 6, 2022 7:42am
Fear and skepticism are riding the surface alongside confidence as the upside tides come in and downside go out
Indications: 4 Negative Indications, 2 BUYs and don’t let Dip, with 1 Pump/Promote (BSTG – the usual suspect)
No tunnel vision here, this analyst/journalist gets into the weeds of daily share pricing and root causes
Why do I keep writing this blog/newsletter to inform investors, what they need to hear that others won’t say or write!
8:00 a.m. edition
Remember that overnight and pre-open actions in futures don't necessarily translate into actual trading in the coming day’s session.
Dow futures are DOWN -0.48% or (-147 points), S&P futures are DOWN -0.49% or (-18 points) and NASDAQ futures are DOWN -0.42% or (-49 points) early in the pre-open – so far,
U.S. stock futures dipped Thursday,
European stocks swung lower
Asia-Pacific stocks were mostly higher, Mainland China markets are closed for a holiday this week.
Henry’omics:
U.S. indexes were down and mixed until staging a reversal to fall back to the downside at the close in the final hour of trading Wednesday.
Indexes started the week on a high note, with the S&P 500 staging its biggest two-day rally since 2020. Stocks fought to keep the winning streak going Wednesday but ultimately fell short. The Dow closed about 42 points lower, or 0.14%. The S&P 500 fell 7.65 points of -20% and the Nasdaq slid -27.77 points or -0.25%
Economic Data Docket: Challenger Job Cuts, year-over-year, September (30.3% during prior month); Initial Jobless Claims, week ended Oct. 1 (203,000 expected, 193,000 during prior week); Continuing Claims, week ended Sep. 24 (1.387 million expected, 1.347 million during prior week)
RegMed Investors’ (RMi) closing bell: “another I warned you so … as the cell and gene therapy sector greased the skids downward in a volatile session.” … https://www.regmedinvestors.com/articles/12636
Ebb and flow:
Q4 – 2 positive and 1 negative closes
Q3/22 –
· September – 1 holiday, 10 positive and 11 negative closes
· August – 1 neutral, 11 positive and 11 negative closes
· July - 1 holiday, 10 negative and 10 positive closes
Companies in my headlights – It’s your decision; I provide ideas and context: INDICATIONS
Maintain BUY and don’t let it dip:
Agenus (AGEN) closed up again +$0.16 to $2.37 after Tuesday’s +$0.12, Monday’s +$0.04, Friday’s -$0.01 and last Thursday’s -$0.14 with a positive +$0.01 or +0.42% pre-open indication,
Solid Biosciences (SLDB) closed down -$0.022 to $0.48 after Tuesday’s +$0.015, Monday’s +$0.0284 and last Friday’s -$0.0016 with a positive +$0.02 or +4.70% pre-open indication after merger/acquisition of AvantiBio and a $75 million Bain financing
Negative Indications:
CRISPR Therapeutics (CRSP) closed down -$1.04 to $64.63 after Tuesday’s +$2.57, Monday’s -$2.25, Friday’s +$0.86 and last Thursday’s -$2.45 with a negative -$0.79 or -1.22% pre-open indication,
Intellia Therapeutics (NTLA) closed up +$0.04 to $60.92 after Tuesday’s +$5.05, Monday’s -$0.13, Friday’s +$0.67 and last Thursday’s -$3.35 following the previous Wednesday’s +$2.61 and Tuesday’s +$1.83 and Monday’s +$0.28 with a negative -$0.31 or -0.51% pre-open,
uniQure NV (QURE) closed down -$0.17 to $20.11 with a negative -$0.41 or -2.04% pre-open indication,
Verve Therapeutics (VERV) closed up +$0.43 to $36.15 after Tuesday’s +$2.31 to $35.72 after Monday’s -$0.94 with a negative -$0.90 or -2.49% pre-open indication,
Puff/Pump and Promote: Maintaining SELL
Biostage (OTCQB: BSTG) closed down again -$0.45 with 2,705 shares traded after Tuesday’s -$0.39 with 2,300 shares traded, Monday’s -$0.71 with 2,918 shares traded, Friday’s +$0.10 with 2,083 shares traded and last Thursday closed FLAT with 1,100 shares traded <3-month average = 2,220 shares>,
Questions need to be answered and they NEVER are for shareholders; as the First Amendment of the U.S. Constitution does guarantee the “freedom of speech, or of the press” … but I guess NOT to respond?
- Who, WHAT and WHERE are pumping and promoting the “spikes” in volume and share price … coming from?
- What is DST Capital? Is DST Capital really managed by Mrs. bin Zhao of Weston, Mass and Hong Yu, president of BSTG? Is LIU Dong-hai chairman of D. Phone, one of the largest smartphone retailers in China and Dixintong Technology group; the ultimate funder of DST Capital?
- Are Chinese communist bureaucrats from Beijing, China directing the company’s activities with BSTG being their corporate “concubine”?
The BOTTOM LINE: There is STILL many a concern of sentiment and conviction in the cell and gene therapy sector.
I STILL believe the sector is headed into “correction” which means that investors should remain cautious.
The final Q4 is HERE … and then back to earnings season!
I try to keep it simple … and short as I love my coverage list – yet, the truth will set investors free from electronic and algorithm control!
As I continually write, “The real question that should be asked is how many companies are at the end of sentiments … leash?
Start by looking at cell and gene therapy companies trading below cash!”
When it comes time to invest or even hold onto an investment; I’d say … focus on what percentage ownership of stock … NOT options CEOs and management teams own versus their salary and bonus.
As I have written, “I devote a lot of time to the direction of the sector to reckon the geography of my coverage group.” That doesn't mean you should flee entirely to cash, but investors make sure gains don't evaporate thus … be quick to IDENTIFY the coming “losing” positions.
Whether information or intelligence is good, bad or somewhere in between; RMi’s daily report is a primer that may say little or a lot; yet it serves as insurance that all indications are being examined and evaluated.
Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice.
All investments are subject to risks. Investors should consider investment objectives.
Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and its or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions securities referred to in this publication.
